Does Methotrexate Worsen Lung Conditions?
Methotrexate, a common treatment for rheumatoid arthritis, psoriasis, and some cancers, carries a risk of pulmonary toxicity that can exacerbate or mimic existing lung issues. This includes hypersensitivity pneumonitis, interstitial lung disease, and acute pneumonitis, occurring in 0.1-11% of rheumatoid arthritis patients on low-dose therapy.[1][2] Patients with pre-existing lung disease, such as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), face heightened risk of deterioration, with studies showing accelerated lung function decline and increased mortality.[3]
How Does Methotrexate Affect the Lungs?
It triggers inflammation and fibrosis through mechanisms like direct cytotoxicity to alveolar cells, immune-mediated hypersensitivity, and oxidative stress. Symptoms often appear subacutely (weeks to months after starting), including dry cough, dyspnea, fever, and hypoxemia. In those with baseline conditions like COPD or idiopathic pulmonary fibrosis, it can worsen gas exchange and radiographic infiltrates, sometimes irreversibly.[1][4]
What Do Studies Show for Pre-Existing Conditions?
A 2020 meta-analysis of RA patients found methotrexate linked to a 1.7-fold higher risk of ILD progression in those with prior lung involvement, though low-dose use (<15 mg/week) had lower odds than high-dose.[3] Case reports document fatal exacerbations in patients with scleroderma-related lung fibrosis. Guidelines from the American College of Rheumatology recommend pulmonary function tests (PFTs) before and during therapy for at-risk patients.[2]
Who Is Most at Risk?
Higher risks apply to older patients (>65), smokers, those on concurrent DMARDs like leflunomide, or with underlying RA-ILD (prevalence up to 40% in RA). Genetic factors like MTHFR polymorphisms may predispose some.[1][4] Baseline high-resolution CT or PFT abnormalities signal caution.
How to Monitor and Manage Risks
Screen with chest imaging and PFTs pre-treatment; monitor for symptoms every 4-8 weeks initially. Discontinue if lung function drops >10-20% or new infiltrates appear—most cases improve after stopping, but steroids may be needed for severe reactions.[2] Alternatives like leflunomide or biologics (e.g., rituximab) are considered for high-risk patients.
When to Avoid or Switch Treatments
Avoid in active lung infections, severe fibrosis, or recent hypersensitivity. The British Society for Rheumatology advises against starting in moderate-severe RA-ILD.[5]
[1] Methotrexate-induced lung injury - PubMed
[2] ACR Guidelines for RA Treatment
[3] Methotrexate in RA-ILD: A Systematic Review - Arthritis Rheum
[4] Pulmonary Toxicity of Methotrexate - UpToDate
[5] BSR Methotrexate Guidelines